Thomas Tray compensation by year
INCYTE Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $358,189 |
| Bonus | $0 |
| Stock awards | $305,897 |
| Option awards | $154,623 |
| Non-equity incentive | $149,423 |
| Pension and deferred compensation | $0 |
| All other | $22,236 |
| Total | $990,368 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: INCYTE CORP DEF 14A filed April 28, 2026, accession 0000879169-26-000031, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 15,166 | $1,497,945 | — |
| RSU | 4,482 | $442,687 | — |
| RSU | 3,805 | $375,820 | — |
| RSU | 3,008 | $297,100 | — |
| RSU | 2,833 | $279,815 | — |
| RSU | 1,038 | $102,523 | — |
| Option | 410 | — | $77.67 |
| Option | 433 | — | $83.20 |
| Option | 2,454 | — | $68.25 |
| Option | 1,665 | — | $61.76 |
| Option | 1,794 | — | $61.18 |
| Option | 2,444 | — | $64.25 |
Per the Outstanding Equity Awards at Fiscal Year-End table in INCYTE CORP's FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 13 award rows shown.
Insider transactions since the last proxy
9 Form 4 lines since the FY2025 proxy (filed April 28, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-07-16 | Grant or award | — | 2,834 | $0.00 | 21,699 |
| 2026-07-16 | Grant or award derivative | — | 4,079 | $0.00 | 4,079 |
| 2026-07-15 | Tax withholding | — | 1,098 | $115.09 | 18,865 |
| 2026-07-14 | Tax withholding | — | 692 | $114.88 | 19,963 |
| 2026-07-02 | Tax withholding | — | 477 | $116.86 | 20,655 |
| 2026-06-04 | Exercise or conversion derivative | 10b5-1 | 2,639 | $0.00 | 0 |
| 2026-06-04 | Sale | 10b5-1 | 2,639 | $100.00 | 21,132 |
| 2026-06-04 | Exercise or conversion | 10b5-1 | 2,639 | $83.83 | 23,771 |
The 8 most recent of 9 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
INCYTE’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| William Meury | Chief Executive Officer | $32,085,952 |
| Mohamed Issa | Executive Vice President and Head of U.S. Commercial | $10,592,782 |
| Pablo Cagnoni | President and Global Head of Research and Development | $8,838,961 |
| Herve Hoppenot | Former President and Chief Executive Officer | $6,380,525 |
| Steven Stein | Executive Vice President, Chief Medical Officer and Head of Late-stage Development | $6,304,172 |
| Christiana Stamoulis | Former Executive Vice President and Chief Financial Officer | $4,936,550 |
| Thomas Tray · this page | Vice President, Chief Accounting Officer and Principal Financial Officer | $990,368 |
The full INCYTE compensation record
free company briefThis page is one person within INCYTE's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order INCYTE's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are INCYTE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat